Cases & Deals

  • Home
  • Practices
  • VasoRx develops patent portfolios relating to lipid nanoparticles for RNA-based therapies

Share

VasoRx develops patent portfolios relating to lipid nanoparticles for RNA-based therapies

April 2023

Client(s) VasoRX, Inc.

Jones Day is representing VasoRx, Inc. in connection with the development of patent portfolios relating lipid nanoparticles (LNP) and their use in the delivery of RNA-based therapeutics (e.g., RNAi, siRNA and miRNA) to endothelial cells for the treatment of vascular disorders, such as cardiovascular diseases and pulmonary arterial hypertension (PAH).

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.